Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 2

Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance

Authors Carew JS, Nawrocki ST, Giles FJ, Cleveland JL

Published 6 June 2008 Volume 2008:2(2) Pages 201—204

DOI https://doi.org/10.2147/BTT.S1840


Jennifer S Carew1, Steffan T Nawrocki1, Francis J Giles1, John L Cleveland2

1The CTRC Institute for Drug Development, University of Texas Health Science Center San Antonio, San Antonio, TX, USA; 2The Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL, USA

Abstract: Autophagy is an ancient, intracellular degradative system which plays important roles in regulating protein homeostasis and which is essential for survival when cells are faced with metabolic stress. Increasing evidence suggests that autophagy also functions as a tumor suppressor mechanism that harnesses the growth and/or survival of cells as they transition towards a rapidly dividing malignant state. However, the impact of autophagy on cancer progression and on the efficacy of cancer therapeutics is controversial. In particular, although the induction of autophagy has been reported after treatment with a number of therapeutic agents, including imatinib, this response has variously been suggested to either impair or contribute to the effects of anticancer agents. More recent studies support the notion that autophagy compromises the efficacy of anticancer agents, where agents such as chloroquine (CQ) that impair autophagy augment the anticancer activity of histone deacetylase (HDAC) inhibitors and alkylating agents. Inhibition of autophagy is a particularly attractive strategy for the treatment of imatinib-refractory chronic myelogenous leukemia (CML) since a combination of CQ with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) compromises the survival of even BCR-ABL-T315I+ imatinib-resistant CML. Additional studies are clearly needed to establish the clinical utility of autophagy inhibitors and to identify patients most likely to benefit from this novel therapeutic approach.

Keywords: autophagy, imatinib, resistance, chronic myelogenous leukemia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]